je.st
news
Tag: melanoma
Midwest Melanoma Partnership and Accelovance, Inc. Enhance Melanoma...
2015-09-15 12:48:54| Biotech - Topix.net
The strategic alliance provides pharmaceutical and biotechnology companies with enhanced access to melanoma key opinion leaders, expedited contracting and protocol review within MMP's 19 academic and community-based research center members, and Accelovance's oncology-experienced clinical and project staff within , MD, PhD, Chairman of the Midwest Melanoma Partnership, stated, "MMP is excited to partner with Accelovance to provide this comprehensive offering to drug development companies. Facilitating expanded access to medical and scientific feedback and expediting clinical trial initiation ultimately provides an enhanced opportunity to advance treatment options for our patients suffering from melanoma."
Tags: partnership
enhance
midwest
melanoma
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
2015-08-18 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
European Commission Approves Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma
2015-07-22 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Demonstrated Superior Survival versus Ipilimumab in a Phase 3 Clinical Trial KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma in adults. The European Commission approval of KEYTRUDA is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestor:Joseph Romanelli, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
european
commission
Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma
2015-07-01 08:13:50| drugdiscoveryonline Home Page
Immunocore Limited and Eli Lilly and Company recently announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma
Tags: trial
clinical
collaboration
announce
Bristol's Melanoma Drug Combo Is A Cancer Breakthrough. Who Will Get It And Who Won't?
2015-05-31 15:28:09| Biotech - Topix.net
A new cancer treatment from Bristol-Myers Squibb saved Gary McLaughlin's life, but it also landed him in the hospital. Mclaughlin, 75, developed melanoma, the deadly skin cancer, just as he was retiring for real.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »